Drug Shortages Approach an All-Time High, Leading to Rationing

387

Drug shortages in the United States are causing significant delays in accessing vital treatments, particularly chemotherapy, bypass surgery, and lead-poisoning drugs. The generic drug market, responsible for 90% of domestic prescriptions, is grappling with supply chain disruptions, quality concerns, and financial challenges leading to manufacturing shutdowns. The Biden administration has assembled a team to address these issues, and bipartisan bills are being developed to tackle delays in bringing generic drugs to the market. However, the pursuit of lower prices has resulted in cost-cutting measures that may compromise quality. The FDA underscores the importance of addressing economic issues within the generic drug industry to effectively resolve the shortages. To read more, click here.

Comments are closed.

Skip to toolbar